Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell crawled time : 00:00 save search
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
ITOS | $10.79 2.18% 2.13% 180K
|
Health Technology
|
| O: -1.0%
H: 2.26%
C: -1.29%
eos-984 association cancer cell research preclinical for meeting
AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
abbvie cell biopharma collaboration car-t
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 3.8M
|
Health Technology
|
| O: 0.77%
H: 1.52%
C: 0.58%
yescarta t-cell response therapy
CAR T-Cell Study Enabled by 10x Genomics Single Cell Technology Published in Nature Medicine
Published: 2023-07-05 (Crawled : 00:00) - prnewswire.com
TXG | $27.8 -0.5% -0.56% 1.8M
|
Health Technology
|
| O: -2.0%
H: 1.42%
C: 0.28%
t-cell genomics cell technology study
Innovent and IASO Bio Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting
Published: 2023-06-06 (Crawled : 00:00) - prnewswire.com
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.94%
H: 0.27%
C: 0.02%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.45%
H: 0.14%
C: -1.5%
asco cell meeting car-t
ANB032, a novel BTLA agonist monoclonal antibody, inhibited T cell proliferation, reduced inflammatory cytokines, and down modulated BTLA expression on circulating T and B cells in Phase 1, progresses into a Phase 2 study in atopic dermatitis
Published: 2023-05-11 (Crawled : 00:00) - anaptysbio.com
ANAB | $19.66 -1.06% -1.09% 140K
|
Health Technology
|
| O: -0.05%
H: 1.25%
C: -6.27%
anb032 agonist dermatitis cell study
Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting
Published: 2022-12-11 (Crawled : 00:00) - globenewswire.com
SANA | $7.93 4.21% 4.4% 2.1M
|
|
| O: 0.24%
H: 9.42%
C: 6.76%
meeting six technology platform
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
Published: 2022-11-30 (Crawled : 00:00) - globenewswire.com
ACHL | $0.79 0.91% -0.03% 430K
|
Manufacturing
|
| O: 4.46%
H: 0.47%
C: -17.06%
therapeutics
Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
Published: 2022-11-16 (Crawled : 00:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -0.52%
H: 1.45%
C: 1.11%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: -1.45%
H: 2.36%
C: 2.31%
covid-19 candidate vaccine study
10x Genomics Launches BEAM to Improve and Streamline Antibody and T-Cell Receptor Discovery
Published: 2022-11-09 (Crawled : 00:00) - biospace.com/
TXG | $27.8 -0.5% -0.56% 1.8M
|
Health Technology
|
| O: -1.88%
H: 1.76%
C: -4.28%
antibody t-cell genomics
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Demonstrated Modulation of Peripheral T cell Activity and Reduction of Circulating PD-1 high Expressing CD4 and CD8 T cells in a Phase 1 Healthy Volunteer Clinical Trial
Published: 2022-11-08 (Crawled : 00:00) - anaptysbio.com
ANAB | $19.66 -1.06% -1.09% 140K
|
Health Technology
|
| O: 0.68%
H: 0.84%
C: -1.61%
trial
ANB032, a Novel BTLA/HVEM Therapeutic Antibody, Inhibited T cells Derived from Atopic Dermatitis Patients In-vitro
Published: 2022-11-08 (Crawled : 00:00) - anaptysbio.com
ANAB | $19.66 -1.06% -1.09% 140K
|
Health Technology
|
| O: 0.68%
H: 0.84%
C: -1.61%
anb032 in-vitro dermatitis in vitro
Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Several KRAS Mutant Solid Tumors for BMF-219 at AACR Annual Meeting 2022
Published: 2022-03-08 (Crawled : 00:00) - globenewswire.com
BMEA | $10.83 -0.18% 0.09% 490K
|
Professional, Scientific, and T...
|
| O: 3.25%
H: 4.04%
C: 2.25%
bmf-219 solid tumors presentation cel preclinical t-cell pre-clinical
Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
Published: 2021-12-05 (Crawled : 00:00) - prnewswire.com
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: 1.49%
H: 0.0%
C: 0.0%
covid antibody t-cell
Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors
Published: 2021-08-04 (Crawled : 00:00) - globenewswire.com
CELU | News F | $3.06 0.99% -3.88% 26K
|
|
| O: 0.35%
H: 3.9%
C: -8.05%
treatment partnership immunotherapy solid tumors therapy t-cell car-t
Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Published: 2021-04-27 (Crawled : 00:00) - prnewswire.com
MRKR | $4.19 1.21% 3.52% 14K
|
Consumer Services
|
| O: 0.0%
H: 10.53%
C: 8.91%
therapy t-cell
The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy
Published: 2021-02-24 (Crawled : 00:00) - biospace.com/
BMY | $49.14 0.43% 0.2% 6.4M
|
Health Technology
|
| O: 0.3%
H: 3.32%
C: 2.78%
BLUE | $0.9536 -6.51% -6.61% 4.1M
|
Health Technology
|
| O: 2.65%
H: 1.48%
C: -1.44%
phase 2 therapy results t-cell car-t cel
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
PROK | $2.72 33.33% 24.58% 2.6M
|
MIGI | $1.57 31.93% 24.2% 660K
|
Information
Your saved searches
Save your searches and get alerts when important news are released.